| scholarly article | Q13442814 |
| P50 | author | Olivier Cristeau | Q61697281 |
| P2093 | author name string | Mondher Toumi | |
| Cécile Rémuzat | |||
| Dan Ionescu | |||
| Julie Dorey | |||
| Guerric Radière | |||
| P2860 | cites work | Biosimilar competition: lessons from Europe | Q87133468 |
| Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis | Q87375385 | ||
| Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? | Q26863707 | ||
| Biosimilars: How Can Payers Get Long-Term Savings? | Q28834400 | ||
| Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe | Q35069447 | ||
| How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013. | Q36034344 | ||
| Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. | Q38209872 | ||
| Incentives for market penetration of biosimilars in Belgium and in five European countries | Q38308835 | ||
| Use of biologics for psoriasis in Central and Eastern European countries | Q38586836 | ||
| Postmarket policy considerations for biosimilar oncology drugs | Q38693911 | ||
| Biosimilars: A Multidisciplinary Perspective | Q38778909 | ||
| Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. | Q39455869 | ||
| Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience | Q46086372 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P304 | page(s) | 1272308 | |
| P577 | publication date | 2017-01-30 | |
| P1433 | published in | Journal of market access & health policy | Q27727071 |
| P1476 | title | Key drivers for market penetration of biosimilars in Europe | |
| P478 | volume | 5 |
| Q48250617 | A randomised trial comparing the pharmacokinetics and safety of the biosimilar CT-P6 with reference trastuzumab. |
| Q52447008 | An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis. |
| Q64106987 | Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? |
| Q52651099 | Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future. |
| Q61810432 | Biosimilars: Considerations for Payers |
| Q57191804 | Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis |
| Q64899490 | Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting. |
| Q100395102 | Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis |
| Q88698802 | Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust |
| Q91588637 | Intact and middle-down CIEF of commercial therapeutic monoclonal antibody products under non-denaturing conditions |
| Q55212098 | Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. |
| Q47173303 | Policies for biosimilar uptake in Europe: An overview. |
| Q33775526 | Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries |
| Q92177218 | Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada |
| Q39455869 | Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. |
| Q93139736 | The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars |
| Q98177418 | Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries? |
Search more.